Fig. 6.

IL-2 complex recovers antitumor effect of immunochemotherapy impaired by steroids in HNSCC mouse model.(A) Experimental schema. C57BL/6 mice intradermally injected with MOC1 (1 × 10⁶) were administered intraperitoneally with IL-2 Cx 3 times every other day for 1 cycle in addition to CDDP, anti-PD-1 Ab, and dexamethasone as indicated in Fig. 1.(B) Tumor growth curves. Control PBS (Red), combination therapy with CDDP and anti-PD-1 Ab (Blue), tri-combination therapy with CDDP, anti-PD-1 Ab and dexamethasone (Yellow), and quad-combination therapy with CDDP, anti-PD-1 Ab, dexamethasone, and IL-2 complex (Green) (n = 4 or 5 /group). Bars and error bars indicate the mean and SD, respectively (**p<0.01, one-way ANOVA).